The Medicines and Healthcare products Regulatory Agency (MHRA) today issued a class 2 pharmacy level medicines recall for Emerade 150, 300 and 500 microgram solution for injection in prefilled syringe.

Pharmaswiss Ceska, an affiliate to Bausch & Lomb UK Limited, is recalling all unexpired batches of the products due to an error in one component of the autoinjector believed to cause some pens to fail to activate and deliver adrenaline.

“Emerade stock held by patients is not being recalled, and patients and caregivers in possession of Emerade pens need to be informed of updated safety information about the risk of failure to activate,” an MHRA statement read.

Pharmacists are asked to stop supplying the products immediately, quarantine remaining stock and return it the supplier using the approved process.

If you want to share your stories and/or experiences with us, please send an email to [email protected]